[The efficacy and tolerability of extended release carbamazepine in adult patients with new-onset epilepsy using epileptiform activity index].

Carbamazepine is an effective and promising drug for initial monotherapy of FE. Its use in the treatment of FE results in a 4.3-fold decrease of EAI (p<0.001), which reflects the efficacy of treatment. EAI is an additional objective measure of treatment efficacy.